Claims for Patent: RE39128

Summary for Patent: RE39128

Title:	Pleuromutilin derivatives as antimicrobials
Abstract:	The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
Inventor(s):	Berry; Valerie Joan (San Diego, CA), Dabbs; Steven (Harlow, GB), Frydrych; Colin Henry (Sawbridgeworth, GB), Hunt; Eric (Great Dunmow, GB), Sanderson; Francis Dominic (Harlow, GB), Woodnutt; Gary (San Diego, CA)
Assignee:	SmithKline Beecham p.l.c. (Brentford, GB)
Application Number:	10/631,707
Patent Claims:	1. A compound of general formula (IA) or (IB): ##STR00010## in which: each of n and m is independently 0, 1 or 2; .[.and.]. X is selected from --O--, .Iadd.--S--, .Iaddend.--S(O)--, --SO.sub.2--, --CO.O--, --NH--, --CONH--, --NHCONH-- and a bond; .[.or n is 1 or 2 and m is 2 and X is --S--; and.]. R.sup.1 is vinyl or ethyl; R.sup.2 is optionally substituted quinuclidinyl, azabicyclo[2.2.1]heptyl, azabicyclo[4,3,0]nonyl, azabicyclo[3.2.1]octyl, azabicyclo[3,3,0]octyl, azabicyclo[2.2.2]octyl, azabicyclo[3.2.1]octenyl, azabicyclo[3.3.1]nonyl or azabicyclo[4.4.0]decyl; .Iadd.wherein R.sup.2 is attached through a ring carbon atom;.Iaddend. R.sup.3 is H or OH; or the moiety R.sup.2(CH.sub.2).sub.mX(CH.sub.2).sub.nCH.sub.2COO at position 14 of (IA) or (IB) is replaced by R.sup.aR.sup.bC=CHCOO in which one of R.sup.a and R.sup.b is hydrogen and the other is R.sup.2 or R.sup.a and R.sup.b together form R.sup.2; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1 in which R.sup.2 is substituted by alkyl, alkyloxy, alkenyl or alkenyloxy, which are optionally further substituted by one or more groups selected from aryl, heterocyclyl, (C.sub.1-6)alkoxy, (C.sub.1-6)alkylthio, aryl(C.sub.1-6)alkoxy, aryl(C.sub.1-6)alkylthio, amino, mono- or di-(C.sub.1-6)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, amides of carboxy, ureido, carbamimidoyl (amidino), guanidino, alkyl-sulfonyl, aminosulfonyl (C.sub.1-6)acyloxy, (C.sub.1-6)acylamino, azido, hydroxy, and halogen. 3. A compound according to claim 1 in which n is 0. 4. A compound according to claim 1 in which m is 0 or 1. 5. A compound according to claim 1 in which R.sup.2 is quinuclidinyl. 6. A compound according to claim 1 which has the formula (IA). .[.7. A compound according to claim 1 selected from: mutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate; 19,20-dihydromutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate; mutilin 14-(quinuclidin-3-yloxy)-acetate; mutilin 14-(quinuclidin-3-ylsulfonyl)-acetate; mutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate; mutilin 14-[N-(2,2-dimethylazabicyclo[4.3.0]non-4-ylmethyl)]-aminoacetate; mutilin 14-(quinuclidin-4-ylcarbonylamino)-acetate; mutilin 14-[(3R,4R)-azabicyclo[2.2.1]hept-3-ylcarbonylamino]-acetate; mutilin 14-(quinuclidin-4-ylmethylsulfanyl)-acetate; 19,20-dihydromutilin 14-(quinuclidin-4-ylsulfonyl)acetate; 19,10-dihydromutilin 14-(quinclidin-4-ylsulfoxy)-acetate; mutilin 14-{(3RS,4SR)-1-aza-bicyclo[2.2.1]hept-3-yl-sulfanyl}-acetate; mutilin 14-(quinuclidin-3-ylidene)-acetate; mutilin 14-[quinuclidin-3-yl]-acetate; mutilin 14-[quinuclidin-3-ylacetoxy]-acetate; mutilin 14-(quinuclidin-3-ylmethylsulfanyl)-acetate; 1,2-didehydromutilin 14-(quinuclidin-4-ylsulfanyl)-acetate; 2.alpha.-hydroxymutilin 14-(quinuclidin-4-ylsulfanyl)-acetate; mutilin 14-(quinuclidin-4-yl)-acetate; mutilin 14-(quinuclidin-4-ylmethyl)-aminoacetate; mutilin 14-[3-(quinuclidin-4-yl)-acrylate; mutilin 14-[3-(quinuclidin-4-yl)]-propionate; mutilin 14-(quinuclidin-4-ylmethyloxy)-acetate; mutilin 14-[(3R)-quinuclidin-3-ylamino]-acetate; mutilin 14-(quinuclidin-4-yl-amino)-acetate; mutilin 14-[(3R)-quinuclidin-3-ylamino )]-acetate; mutilin 14-(quinuclidin-4-yl-amino)-acetate; mutilin 14-[4-(quinuclidin-4-yl)]-butyrate; mutilin 14-(1-azabicyclo[3,3,0]oct-4-ylmethylsulfanyl)-acetate; mutilin 14-(1-azabicyclo[3,3,0]oct-3-ylsulfanyl)-acetate; mutilin 14-(endo 8-methyl-8-azabicyclo[3,2,1]oct-3-ylsulfanyl)-acetate; mutilin 14-(1-azabicyclo[4,3,0]non-4-ylsulfanyl)-acetate; 19,20-dihydromutilin 14-(1-azabicyclo[4,3,0]non-4-ylsulfanyl)-acetate; mutilin 14-{(3S,4R)-1-azabicyclo[2.2.1]hept-3-ylmethylsulfanyl}-acetate; mutilin 14-(quinuclidin-2-ylmethylsulfanyl)-acetate; mutilin 14-(1-azabicyclo[2.2.1]hept-4-ylmethylsulfanyl)-acetate; mutilin 14-{(3R,4S)-1-azabicyclo[2.2.1]hept-3-ylmethylsulfanyl}-acetate; mutilin 14-(1-azabicyclo[3.2.1]oct-5-ylmethylsulfanyl)-acetate; mutilin 14-(quinuclidin-4-ylmethylsulfanyl)-acetate; mutilin 14-(8-methyl-8-azabicyclo [3.2.1]oct-3-ylmethylsulfanyl)-acetate; mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate; mutilin 14-[(3-(quinuclidin-4-ylsulfanyl)]-propionate; mutilin 14-[3-(quinuclidin-4-ylmethylsulfanyl)]-propionate; 19,20-dihydromutilin 14-(8-methyl-8-azabicyclo[3.2.1]oct-3-ylmethylsulfanyl)-acetate; mutilin 14-[4-(quinuclidin-4-ylsulfanyl)]-butyrate; and mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate..]. 8. A process for preparing a compound according to claim 1 which comprises: (a) coupling mutilin or epi-mutilin having a protected hydroxy group at position 11, with an active derivative, such as an acid chloride, of a carboxylic acid R.sup.2A--(CH.sub.2).sub.m--X--(CH.sub.2).sub.n--CH.sub.2CO.sub.2H, where R.sup.2A is R.sup.2 as defined in claim 1 or a group convertible thereto, and n, m, and X are as defined in claim 1, and if necessary converting the epi-mutilin to mutilin, and where necessary or desired, before or after the coupling, modifying the mutilin nucleus to introduce 2--OH; 19,20-dihydro; or 1,2-dehydro substituents; or (b) providing a mutilin or epi-mutilin derivative having (CH.sub.2).sub.nCH.sub.2CO as an O-acyl group at position 14, where the acyl group is substituted with R.sup.L, which is a leaving group, OH or NH, coupling the 14-O-acyl-(epi) mutilin derivative with a compound R.sup.2A(CH.sub.2).sub.mXH or an active derivative therof, and if necessary converting the epi-mutilin configuration to mutilin, and where necessary or desired, before or after the coupling, modifying the mutilin nucleus to introduce 2-OH; 19,20-dihydro; or 1,2-dehydro substituents. 9. A process for preparing a compound according to claim 8(b) in which (a) when X is O, S or NH, R.sup.L is a leaving group and is reacted with (i) the alcohol R.sup.2--(CH2).sub.m--OH; (ii) the thiol R.sup.2--(CH.sub.2).sub.m--SH; (iii) the amine R.sup.2--(CH.sub.2).sub.m--NH.sub.2; (b) when X is CONH, R.sup.L is amino and is reacted with the acid R.sup.2A--(CH.sub.2).sub.m--CO.sub.2H, or an acylating agent derived therefrom; (c) when X is CO.O, R.sup.L is hydroxy and is reacted with an acylating agent derived from the acid R.sup.2A--(CH.sub.2).sub.m--CO.sub.2H. 10. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. 11. A pharmaceutical composition according to claim 10 in the form of a spray adapted for administration to the nasal cavity. 12. A pharmaceutical composition according to claim 11 in which the spray is an aqueous spray. 13. A method of treating bacterial infection which method comprises administering an anti-bacterial effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof. 14. A method of reducing or eliminating the nasal carriage of pathogenic organisms which method comprises administering an effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof. 15. A method of prophylaxis of recurrent otitis media or recurrent acute bacterial sinusitis which comprises administering an effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof. .Iadd.16. A compound according to claim 1 wherein X is --S--, n is 0 and m is 0 or 1..Iaddend. .Iadd.17. A pharmaceutical composition according to claim 10 adapted for topical administration..Iaddend. .Iadd.18. A pharmaceutical composition according to claim 17 in the form of an ointment..Iaddend. .Iadd.19. A pharmaceutical composition according to claim 17 in the form of a cream..Iaddend. .Iadd.20. A pharmaceutical composition according to claim 17 in the form of a lotion..Iaddend. .Iadd.21. A method of treating bacterial infections of skin or soft tissue which method comprises topically administering an antibacterially effective amount of a compound of formula (IA) or (IB) according to claim 1 to a patient in need thereof..Iaddend. .Iadd.22. A method according to claim 21 wherein the infection is caused by a Gram-positive bacteria..Iaddend. .Iadd.23. A method according to claim 21 wherein the infection is caused by a Gram-negative bacteria..Iaddend. .Iadd.24. A method according to claim 21 wherein the infection is caused by a mycoplasma..Iaddend. .Iadd.25. The compound mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate..Iaddend. .Iadd.26. A compound selected from mutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate; 19,20-dihydromutilin 14-(quinuclidin-4-yl-sulfanyl)-acetate; mutilin 14-(quinuclidin-3-yloxy)-acetate; mutilin 14-(quinuclidin-3-ylsulfanyl)-acetate; mutilin 14-[N-(2,2-dimethylazabicyclo[4.3.0]non-4-ylmethyl)]-aminoacetate; mutilin 14-(quinuclidin-4-ylcarbonylamino)-acetate; mutilin 14-[(3R,4R)-acabicyclo[2.2.1]hept-3-ylcarbonylamino]-acetate; mutilin 14-(quinuclid-4-ylmethylsulfanyl)-acetate; 19,20-dihydromutilin 14-(quinuclidin-4-ylsulfonyl)acetate; 19,20-dihydromutilin 14-(quinclidin-4-ylsulfoxy)-acetate; mutilin 14-{(3RS,4SR)-1-aza-bicyclo[2.2.1]hept-3-yl-sulfanyl}-acetate; mutilin 14-(quinuclidin-3-ylidene)-acetate; mutilin 14-[quinuclidin-3-yl]-acetate; mutilin 14-[quinuclidin-3-ylacetoxy]-acetate; mutilin 14-(quinuclidin-3-ylmethylsulfanyl)-acetate; 1,2-didehydromutilin 14-(quinuclidin-4-ylsulfanyl)-acetate; 2.alpha.-hydroxymutilin 14-(quinuclidin-4-ylsulfanyl)-acetate; mutilin 14-(quinuclidin-4-yl)-acetate; mutilin 14-(quinuclidin-4-ylmethyl)-aminoacetate; mutilin 14-[3-(quinuclidin-4-yl)-acrylate;] mutilin 14-[3-(quinuclidin-4-yl)]-propionate; mutilin 14-(quinuclidin-4-ylmethyloxy)-acetate; mutilin 14-[(3R)-quinuclidin-3-ylamino]-acetate; mutilin 14-(quinuclidin-4-yl-amino)-acetate; mutilin 14-[4-(quinuclidin-4-yl)]-butyrate; mutilin 14-(1-azabicyclo[3,3,0]oct-4-ylmethylsulfanyl)-acetate; mutilin 14-(1-azabicyclo[3,3,0]oct-3-ylsulfanyl)-acetate; mutilin 14-(endo 8-methyl-8-azabicyclo[3,2,1]oct-3-ylsulfanyl)-acetate; mutilin 14-(1-azabicyclo[4,3,0]non-4-ylsulfanyl)-acetate; 19,20-dihydromutilin 14-(1-azabicyclo[4,3,0]non-4-ylsulfanyl)-acetate; mutilin 14-{(3S,4R)-1-azabicyclo[2.2.1]hept-3-ylmethylsulfanyl}-acetate; mutilin 14-(quinuclidin-2-ylmethylsulfanyl)-acetate; mutilin 14-(1-azabicyclo[2.2.1]hept-4-ylmethylsulfanyl)-acetate; mutilin 14-{(3R,4S)-1-azabicyclo[2.2.1]hept-3-ylmethylsulfanyl}-; mutilin 14-(1-azabicyclo[3.2.1]oct-5-ylmethylsulfanyl)-acetate; mutilin 14-(8-methyl-8-azabicyclo[3.2.1]oct-3-ylmethylsulfanyl)-acetate; mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate; mutilin 14-[(3-(quinuclidin-4-ylsulfanyl)]-propionate; mutilin 14-[3-(quinuclidin-4-ylmethylsulfanyl)]-propionate; 19,20-dihydromutilin 14-(8-methyl-8-azabicyclo[3.2.1]oct-3-ylmethylsulfanyl)-acetate; and mutilin 14-[4-(quinuclidin-4-ylsulfanyl)]-butyrate; or a pharmaceutically acceptable salt thereof..Iaddend.